摘要
目的:评价白芍总苷辅助预防大鼠心脏移植排斥反应的作用。方法:将心脏移植后的大鼠随机分为对照组、他克莫司组、白芍总苷组以及他克莫司与白芍总苷合用组,观察各组供心存活时间,于术后第7天获取部分供心做病理学检查,并检测各组受体外周血T淋巴细胞亚群及受体的肝肾功能。结果:供心存活时间,他克莫司与白芍总苷合用组为(13.57±1.99)d,明显长于他克莫司单用组的(11.14±1.57)d(P<0.05)。他克莫司与白芍总苷合用组病理切片表明其排斥反应明显轻于他克莫司组。术后第7天,他克莫司与白芍总苷合用组外周血T淋巴细胞亚群中CD4^-T淋巴细胞的百分比为(32.43±4.39)%,明显低于他克莫司组的(38.71±5.15)%(P<0.05);外周血T淋巴细胞亚群中CD8^+T淋巴细胞的百分比和肝肾功能与他克莫司组比较差异无统计学意义(P>0.05)。结论:白芍总苷和他克莫司联合应用对大鼠心脏移植排斥反应的预防作用优于他克莫司的单一用药,且毒副作用不增加。
Objective： To evaluate the role of total glucosides of peony （TGP） as.adjuvant therapy for prevention of cardiac allograft rejection in rats.
Methods： Rats with cardiac allograft were randomly divided into control group, tacrolimus-treated group, TGP-treated group and tacrolimus plus TGP-treated group. Graft survival time was observed. AIIografts in some cases were examined by histological study seven days after transplantation. At the same time, the levels of CD4^＋ and CD8^＋ T cell subsets in peripheral blood were examined by using flow cytometry; the hepatic function and renal function of recipients were also tested.
Results： The graft survival time of the tacrolimus-treated group and tacrolimus plus TGP-treated group was （11.144-1.57） d and （13.57±1.99） d, respectively. The graft survival time of the tacrolimus plus TGP- treated group was longer than that of the tacrolimus-treated group （P〈0. 05）. The histological study showed that the rejection of the tacrolimus plus TGP-treated group was slighter than that of the tacrolimus-treated group. The levels of CD4^＋ T cell subset in the peripheral blood of the tacrolimus-treated and tacrolimus plus TGP-treated groups were （38.7±5. ]5）% and （32. 43±4.39）% respectively 7 days after transplantation. The level of CD^4＋T cell subset in the tacrolimus plus TGP-treated group was lower than that in the tacrolimus-treated group （P〈0. 05）. The level of CD8^＋ T cell subset and the hepatic and renal function had no significant differences between the tacrolimus-treated group and the tacrolimus plus TGP-treated group.
Conclusion ： Effects of tacrolimus plus TGP in prevention of rejection are better than tacrolimus monotherapy in rats with cardiac allograft and without increasing side effects.
出处
《中西医结合学报》
CAS
2007年第5期581-584,共4页
Journal of Chinese Integrative Medicine
基金
黑龙江省卫生厅科研基金(No.2003-057)
哈尔滨市科学研究基金(No.2003AFQXJ040)
关键词
心脏移植
白芍
他克莫司
抗排斥治疗
heart transplantation
Radix Paeoniae Alba
tacrolimus
antirejection therapy
